HC Wainwright & Co. Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $14

Benzinga Newsdesk www.benzinga.com Neutral 65.2%

Neg 0% Neu 65.2% Pos 0%

HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Immuneering (NASDAQ:IMRX) with a Buy rating and announces Price Target of $14.